MSI-L/dMMR + KRAS G12V
|
CRC
|
MSI-L/dMMR + KRAS G12V
|
CRC
|
nivolumab + ipilimumab + regorafenib Sensitive: C4 – Case Studies
|
nivolumab + ipilimumab + regorafenib Sensitive: C4 – Case Studies
|
MSI-L/dMMR + KRAS G12V
|
CRC
|
MSI-L/dMMR + KRAS G12V
|
CRC
|
FOLFIRI Resistant: C4 – Case Studies
|
FOLFIRI Resistant: C4 – Case Studies
|